Private, ophthalmology focused early stage company; technology out of Johns Hopkins. Planning 4Q19 IND and 1Q20 Ph1/2 initiation (DME and Wet AMD). AXT107: novel peptide inhibiting VEGF and activating Tie2; demonstrated efficacy and durability in rabbit and mouse models.
301 West 29th Street
Baltimore, MD 21211
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019